
Gaudium IVF IPO
- Issue price
- ₹79
- Listing price
- ₹83
- +5.06%
- Current price
- ₹105.95
- +34.11%
- Subscribed
- 7.27x
- Issue size
- ₹165 Cr
- Listed on
- 27 Feb 2026
IPO timeline
- Opens20 FebFri
- Closes24 FebTue
- Allotment25 FebWed
- Refunds26 FebThu
- Demat credit26 FebThu
- Listing27 FebFri
Issue details
- Price band
- ₹75 – ₹79 per share
- Issue size
- ₹165 Cr
- Fresh issue
- ₹90 Cr · 1.14 Cr shares
- Offer for sale
- ₹75 Cr
- Issue type
- Fresh capital cum OFS
- Face value
- ₹5 per share
- Lot size
- 189 shares
- Minimum investment
- ₹14,931
- Listing on
- NSE & BSE
- Exchange code
- GAUDIUMIVF.BO · 7603
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 189 | ₹14,931 |
| Retail (Max) | 13 | 2,457 | ₹1,94,103 |
| S-HNI (Min) | 14 | 2,646 | ₹2,09,034 |
| B-HNI (Min) | 67 | 12,663 | ₹10,00,377 |
Reservation
- QIB
- 1,04,43,100 shares (50.00% of the Offer)
- NII
- 31,32,930 shares (15.00% of the Offer)
- Retail
- 73,10,170 shares (35.00% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on Bigshare Services- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 25 Feb 2026
- Refunds initiated
- 26 Feb 2026
- Shares credited to demat
- 26 Feb 2026
- Listing
- 27 Feb 2026
Grey market premium (GMP)
- Current GMP
- ₹-5
- -6.00%
- Estimated listing price
- ₹74
- Issue price ₹79
- Highest
- ₹15
- 17 Feb
- Lowest
- ₹-5
- 26 Feb
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 27 Feb 2026 | ₹-5 | -6.00% | ₹74 |
| 26 Feb 2026 | ₹-5 | -6.00% | ₹74 |
| 25 Feb 2026 | ₹-2 | -3.00% | ₹77 |
| 24 Feb 2026 | ₹4 | +5.00% | ₹83 |
| 23 Feb 2026 | ₹5 | +6.00% | ₹84 |
| 22 Feb 2026 | ₹8 | +10.00% | ₹87 |
| 21 Feb 2026 | ₹8 | +10.00% | ₹87 |
| 20 Feb 2026 | ₹8 | +10.00% | ₹87 |
| 19 Feb 2026 | ₹9 | +11.00% | ₹88 |
| 18 Feb 2026 | ₹12 | +15.00% | ₹91 |
| 17 Feb 2026 | ₹15 | +19.00% | ₹94 |
| 16 Feb 2026 | ₹0 | — | ₹79 |
| 14 Feb 2026 | ₹0 | — | ₹79 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB1.62x
- NII (HNI)14.05x
- Retail7.6x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 41,77,240 | 67,67,129 | 1.62x |
| Non-Institutional Investors (NII) | 31,32,930 | 4,40,17,667 | 14.05x |
| bNII — bids above ₹10 Lakh | 20,88,620 | 2,65,46,360 | 12.71x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 10,44,310 | 1,74,71,306 | 16.73x |
| Retail Individual Investors (RII) | 73,10,170 | 5,55,57,292 | 7.6x |
| Total | 1,46,20,340 | 10,62,89,872 | 7.27x |
Financials
- P/E Ratio
- 22.99
- EPS (₹)
- 3.12
- RoCE
- 39.70
- RoNW
- 41.71
- PAT Margin
- 26.96
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 sep 2025 | 31 Mar 25 | 31 Mar 24 |
|---|---|---|---|
| Revenue | 49.75 | 70.96 | 48.15 |
| OPM % | |||
| EBITDA | 18.95 | 28.63 | 19.27 |
| Net Profit | 12.51 | 19.13 | 10.32 |
| Debt | 22.51 | 15.60 | 26.00 |
| Assets | 106.62 | 88.51 | 51.01 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Gaudium IVF This IPO | ₹165 Cr | 22.99 | 41.71% | 26.96% | 7.27x | +5.06% |
| Hexagon Nutrition Mainboard · listed 12 Jun 2026 | ₹138.87 Cr | 15.35 | 12.12% | 9.81% | 53.68x | +7.22% |
| Kronox Lab Sciences Mainboard · listed 10 Jun 2024 | ₹130.15 Cr | 24.47 | 25.66% | 22.60% | 117.25x | +21.29% |
| Amanta Healthcare Mainboard · listed 9 Sep 2025 | ₹126 Cr | 46.59 | 10.89% | 3.86% | 82.6x | +7.14% |
| Anlon Healthcare Mainboard · listed 3 Sep 2025 | ₹121.03 Cr | 23.57 | 25.51% | 17.06% | 7.12x | +1.10% |
| Gujarat Kidney & Super Speciality Mainboard · listed 30 Dec 2025 | ₹250.8 Cr | 61.62 | 36.61% | 23.61% | 5.21x | +5.26% |
| Sai Parenteral's Mainboard · listed 2 Apr 2026 | ₹409 Cr | 72.19 | 5.09% | 8.93% | 1.08x | +2.04% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Gaudium IVF plans to use the money raised, as stated in the offer document.
- Funding capital expenditure towards establishment of New IVF Centers of the Company₹50 Cr
- Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and₹20 Cr
- General Corporate Purpose
About Gaudium IVF
Gaudium IVF is a rapidly growing fertility care provider in India, focused on offering advanced reproductive treatments with a patient-centric approach. The company was founded by Dr. Manika Khanna, a well-known fertility expert, with the aim of making high-quality infertility treatments accessible and affordable. Since its inception, Gaudium IVF has expanded its footprint across multiple cities, building a strong reputation for ethical practices, transparent processes, and high success rates. The organisation combines medical expertise with modern infrastructure to address a wide range of fertility challenges faced by couples. The company offers a comprehensive suite of services including IVF (in-vitro fertilisation), IUI (intrauterine insemination), ICSI, egg freezing, fertility preservation, and advanced diagnostic solutions. Its business model is primarily clinic-based, generating revenue through treatment cycles, consultations, and specialised procedures. Gaudium IVF focuses on personalised treatment plans, leveraging technology and experienced medical professionals to improve outcomes. By maintaining quality standards and expanding through new centres and partnerships, the company aims to strengthen its presence in India’s growing fertility services market while ensuring consistent patient care and long-term trust.
Promoters and shareholding
The Promoters of the company are Dr. Manika Khanna, Dr. Peeyush Khanna and Vishad Khanna.
- Shares outstanding, pre-issue
- 6,13,94,384
- Shares outstanding, post-issue
- 7,27,86,884
Anchor investors
| Investor | Shares allotted | Amount | % of anchor book |
|---|---|---|---|
| MERU INVESTMENT FUND PCC-CELL 1 | 21,51,330 | ₹17 Cr | 34.33% |
| SANSHI FUND-I | 15,82,308 | ₹12.5 Cr | 25.25% |
| HORNBILL ORCHID INDIA FUND | 12,66,300 | ₹10 Cr | 20.21% |
| CARNELIAN INDIA MULTI STRATEGY FUND | 12,65,922 | ₹10 Cr | 20.2% |
Registrar, lead managers and documents
Lead manager
Company contact
Gaudium IVF & Women Health Ltd. Address B1/51, Janak Puri, B-1, New Delhi, New Delhi, 110058
011-4885 8585
compliance@gaudiumivfcentre.comGaudium IVF IPO: common questions
1.When does the Gaudium IVF IPO open and close?
The Gaudium IVF IPO opens on 20 Feb 2026 and closes on 24 Feb 2026.
2.What is the price band of the Gaudium IVF IPO?
The price band is ₹75 – ₹79 per share, with a lot size of 189 shares and a minimum investment of ₹14,931.
3.What is the size of the Gaudium IVF IPO?
The issue size is ₹165 Cr (Fresh capital cum OFS).
4.What is the GMP of the Gaudium IVF IPO?
The last reported grey market premium is ₹-5 per share as of 27 Feb 2026, 09:19 AM IST. GMP is unofficial and changes frequently.
5.When is the Gaudium IVF IPO allotment?
The basis of allotment is expected on 25 Feb 2026. Allotment status can be checked with the registrar, Bigshare Services Private Limited.
6.When will the Gaudium IVF IPO list?
The shares listed on 27 Feb 2026 on NSE & BSE.
7.Who is the lead manager of the Gaudium IVF IPO?
The book running lead manager is Sarthi Capital Advisors Pvt.Ltd., and the registrar is Bigshare Services Private Limited.
8.What will the money raised in the Gaudium IVF IPO be used for?
As stated in the offer document, the proceeds are for: Funding capital expenditure towards establishment of New IVF Centers of the Company; Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company; and; General Corporate Purpose.
9.How can my company launch an IPO like Gaudium IVF?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393